APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics for Severe Asthma

Compare research editions
View pricing & licenses

Selected research

Industry Research

Biologics for Severe Asthma Industry Research Report 2026

28 December 2025121 pages

Choose your research edition.

Industry ResearchBiologics for Severe Asthma Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics for Severe Asthma Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics for Severe Asthma Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics for Severe Asthma Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Biologics for Severe Asthma market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Biologics for Severe Asthma is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Biologics for Severe Asthma is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Biologics for Severe Asthma include Teva Pharmaceuticals, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, GSK, AstraZeneca and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Biologics for Severe Asthma market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Biologics for Severe Asthma Market by Company

Teva Pharmaceuticals

Sanofi

Novartis

Roche

Regeneron Pharmaceuticals

GSK

AstraZeneca

Amgen

Biologics for Severe Asthma Segment by Type

Omalizumab

Benralizumab

Dupirumab

Mepolizumab

Reslizumab

Tezepelumab-ekko

Biologics for Severe Asthma Segment by Application

Clinic

Hospital

Other

Biologics for Severe Asthma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics for Severe Asthma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics for Severe Asthma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics for Severe Asthma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Biologics for Severe Asthma manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Biologics for Severe Asthma by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Biologics for Severe Asthma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biologics for Severe Asthma Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Biologics for Severe Asthma Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Biologics for Severe Asthma Sales Market Share by Manufacturers (2021-2026) Table 8. Global Biologics for Severe Asthma Revenue of Manufacturers (2021-2026) Table 9. Global Biologics for Severe Asthma Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Biologics for Severe Asthma Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Biologics for Severe Asthma Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Biologics for Severe Asthma, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Biologics for Severe Asthma, Product Type & Application Table 14. Global Biologics for Severe Asthma Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Biologics for Severe Asthma by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceuticals Company Information Table 19. Teva Pharmaceuticals Business Overview Table 20. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 22. Teva Pharmaceuticals Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi Biologics for Severe Asthma Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Biologics for Severe Asthma Product Portfolio Table 32. Novartis Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Roche Biologics for Severe Asthma Product Portfolio Table 37. Roche Recent Developments Table 38. Regeneron Pharmaceuticals Company Information Table 39. Regeneron Pharmaceuticals Business Overview Table 40. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 42. Regeneron Pharmaceuticals Recent Developments Table 43. GSK Company Information Table 44. GSK Business Overview Table 45. GSK Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. GSK Biologics for Severe Asthma Product Portfolio Table 47. GSK Recent Developments Table 48. AstraZeneca Company Information Table 49. AstraZeneca Business Overview Table 50. AstraZeneca Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. AstraZeneca Biologics for Severe Asthma Product Portfolio Table 52. AstraZeneca Recent Developments Table 53. Amgen Company Information Table 54. Amgen Business Overview Table 55. Amgen Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Amgen Biologics for Severe Asthma Product Portfolio Table 57. Amgen Recent Developments Table 58. Global Biologics for Severe Asthma Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units) Table 60. Global Biologics for Severe Asthma Sales Market Share by Region (2021-2026) Table 61. Global Biologics for Severe Asthma Sales by Region (2027-2032) & (K Units) Table 62. Global Biologics for Severe Asthma Sales Market Share by Region (2027-2032) Table 63. Global Biologics for Severe Asthma Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Biologics for Severe Asthma Revenue Market Share by Region (2021-2026) Table 65. Global Biologics for Severe Asthma Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Biologics for Severe Asthma Revenue Market Share by Region (2027-2032) Table 67. North America Biologics for Severe Asthma Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 69. North America Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 70. North America Biologics for Severe Asthma Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Biologics for Severe Asthma Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Biologics for Severe Asthma Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 74. Europe Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 75. Europe Biologics for Severe Asthma Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Biologics for Severe Asthma Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Biologics for Severe Asthma Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 79. Asia Pacific Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 80. Asia Pacific Biologics for Severe Asthma Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Biologics for Severe Asthma Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Biologics for Severe Asthma Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 84. South America Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 85. South America Biologics for Severe Asthma Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Biologics for Severe Asthma Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Biologics for Severe Asthma Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 89. Middle East and Africa Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 90. Middle East and Africa Biologics for Severe Asthma Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Biologics for Severe Asthma Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 93. Global Biologics for Severe Asthma Sales by Type (2027-2032) & (K Units) Table 94. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026) Table 95. Global Biologics for Severe Asthma Sales Market Share by Type (2027-2032) Table 96. Global Biologics for Severe Asthma Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Biologics for Severe Asthma Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026) Table 99. Global Biologics for Severe Asthma Revenue Market Share by Type (2027-2032) Table 100. Global Biologics for Severe Asthma Price by Type (2021-2026) & (US$/Unit) Table 101. Global Biologics for Severe Asthma Price by Type (2027-2032) & (US$/Unit) Table 102. Global Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 103. Global Biologics for Severe Asthma Sales by Application (2027-2032) & (K Units) Table 104. Global Biologics for Severe Asthma Sales Market Share by Application (2021-2026) Table 105. Global Biologics for Severe Asthma Sales Market Share by Application (2027-2032) Table 106. Global Biologics for Severe Asthma Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Biologics for Severe Asthma Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2026) Table 109. Global Biologics for Severe Asthma Revenue Market Share by Application (2027-2032) Table 110. Global Biologics for Severe Asthma Price by Application (2021-2026) & (US$/Unit) Table 111. Global Biologics for Severe Asthma Price by Application (2027-2032) & (US$/Unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Biologics for Severe Asthma Distributors List Table 115. Biologics for Severe Asthma Customers List Table 116. Biologics for Severe Asthma Industry Trends Table 117. Biologics for Severe Asthma Industry Drivers Table 118. Biologics for Severe Asthma Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Biologics for Severe Asthma Product Image Figure 5. Global Biologics for Severe Asthma Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Biologics for Severe Asthma Market Size (2021-2032) & (US$ Million) Figure 7. Global Biologics for Severe Asthma Sales (2021-2032) & (K Units) Figure 8. Global Biologics for Severe Asthma Average Price (US$/Unit) & (2021-2032) Figure 9. Omalizumab Product Image Figure 10. Benralizumab Product Image Figure 11. Dupirumab Product Image Figure 12. Mepolizumab Product Image Figure 13. Reslizumab Product Image Figure 14. Tezepelumab-ekko Product Image Figure 15. Clinic Product Image Figure 16. Hospital Product Image Figure 17. Other Product Image Figure 18. Global Biologics for Severe Asthma Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Biologics for Severe Asthma, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Biologics for Severe Asthma Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Biologics for Severe Asthma Sales by Region in 2025 Figure 24. Global Biologics for Severe Asthma Revenue by Region in 2025 Figure 25. North America Biologics for Severe Asthma Market Size by Country in 2025 Figure 26. North America Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 27. North America Biologics for Severe Asthma Revenue Market Share by Country (2021-2032) Figure 28. United States Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Biologics for Severe Asthma Market Size by Country in 2025 Figure 32. Europe Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 33. Europe Biologics for Severe Asthma Revenue Market Share by Country (2021-2032) Figure 34. Germany Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Biologics for Severe Asthma Market Size by Country in 2025 Figure 45. Asia Pacific Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Biologics for Severe Asthma Revenue Market Share by Country (2021-2032) Figure 47. China Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Biologics for Severe Asthma Market Size by Country in 2025 Figure 56. South America Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 57. South America Biologics for Severe Asthma Revenue Market Share by Country (2021-2032) Figure 58. Brazil Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Biologics for Severe Asthma Market Size by Country in 2025 Figure 62. Middle East and Africa Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Biologics for Severe Asthma Revenue Market Share by Country (2021-2032) Figure 64. Egypt Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Biologics for Severe Asthma Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2032) Figure 70. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2032) Figure 71. Global Biologics for Severe Asthma Price (US$/Unit) by Type (2021-2032) Figure 72. Global Biologics for Severe Asthma Sales Market Share by Application (2021-2032) Figure 73. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2032) Figure 74. Global Biologics for Severe Asthma Price (US$/Unit) by Application (2021-2032) Figure 75. Biologics for Severe Asthma Value Chain Figure 76. Biologics for Severe Asthma Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Biologics for Severe Asthma Industry Opportunities and Challenges

Scope & coverage.

Types
  • Omalizumab
  • Benralizumab
  • Dupirumab
  • Mepolizumab
  • Reslizumab
  • Tezepelumab-ekko
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • Regeneron Pharmaceuticals
  • GSK
  • AstraZeneca
  • Amgen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Biologics for Severe Asthma Market Size (2021-2032)
  4. 2.2.2 Global Biologics for Severe Asthma Sales (2021-2032)
  5. 2.2.3 Global Biologics for Severe Asthma Market Average Price (2021-2032)
  6. 2.3 Biologics for Severe Asthma by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Omalizumab
  9. 2.3.3 Benralizumab
  10. 2.3.4 Dupirumab
  11. 2.3.5 Mepolizumab
  12. 2.3.6 Reslizumab
  13. 2.3.7 Tezepelumab-ekko
  14. 2.4 Biologics for Severe Asthma by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Clinic
  17. 2.4.3 Hospital
  18. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Biologics for Severe Asthma Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Biologics for Severe Asthma Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Biologics for Severe Asthma Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Biologics for Severe Asthma Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Biologics for Severe Asthma Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Biologics for Severe Asthma, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Biologics for Severe Asthma, Product Type & Application
  8. 3.8 Global Manufacturers of Biologics for Severe Asthma, Established Date
  9. 3.9 Global Biologics for Severe Asthma Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceuticals
  2. 4.1.1 Teva Pharmaceuticals Company Information
  3. 4.1.2 Teva Pharmaceuticals Business Overview
  4. 4.1.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  6. 4.1.5 Teva Pharmaceuticals Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Biologics for Severe Asthma Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Biologics for Severe Asthma Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Biologics for Severe Asthma Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Regeneron Pharmaceuticals
  26. 4.5.1 Regeneron Pharmaceuticals Company Information
  27. 4.5.2 Regeneron Pharmaceuticals Business Overview
  28. 4.5.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  30. 4.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 4.6 GSK
  32. 4.6.1 GSK Company Information
  33. 4.6.2 GSK Business Overview
  34. 4.6.3 GSK Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 GSK Biologics for Severe Asthma Product Portfolio
  36. 4.6.5 GSK Recent Developments
  37. 4.7 AstraZeneca
  38. 4.7.1 AstraZeneca Company Information
  39. 4.7.2 AstraZeneca Business Overview
  40. 4.7.3 AstraZeneca Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
  42. 4.7.5 AstraZeneca Recent Developments
  43. 4.8 Amgen
  44. 4.8.1 Amgen Company Information
  45. 4.8.2 Amgen Business Overview
  46. 4.8.3 Amgen Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Amgen Biologics for Severe Asthma Product Portfolio
  48. 4.8.5 Amgen Recent Developments
5 Global Biologics for Severe Asthma Market Scenario by Region
  1. 5.1 Global Biologics for Severe Asthma Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Biologics for Severe Asthma Sales by Region: 2021-2032
  3. 5.2.1 Global Biologics for Severe Asthma Sales by Region: 2021-2026
  4. 5.2.2 Global Biologics for Severe Asthma Sales by Region: 2027-2032
  5. 5.3 Global Biologics for Severe Asthma Revenue by Region: 2021-2032
  6. 5.3.1 Global Biologics for Severe Asthma Revenue by Region: 2021-2026
  7. 5.3.2 Global Biologics for Severe Asthma Revenue by Region: 2027-2032
  8. 5.4 North America Biologics for Severe Asthma Market Facts & Figures by Country
  9. 5.4.1 North America Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Biologics for Severe Asthma Sales by Country (2021-2032)
  11. 5.4.3 North America Biologics for Severe Asthma Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Biologics for Severe Asthma Market Facts & Figures by Country
  16. 5.5.1 Europe Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Biologics for Severe Asthma Sales by Country (2021-2032)
  18. 5.5.3 Europe Biologics for Severe Asthma Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Biologics for Severe Asthma Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Biologics for Severe Asthma Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Biologics for Severe Asthma Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Biologics for Severe Asthma Market Facts & Figures by Country
  41. 5.7.1 South America Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Biologics for Severe Asthma Sales by Country (2021-2032)
  43. 5.7.3 South America Biologics for Severe Asthma Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Biologics for Severe Asthma Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Biologics for Severe Asthma Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Biologics for Severe Asthma Sales by Type (2021-2032)
  2. 6.1.1 Global Biologics for Severe Asthma Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Biologics for Severe Asthma Sales Market Share by Type (2021-2032)
  4. 6.2 Global Biologics for Severe Asthma Revenue by Type (2021-2032)
  5. 6.2.1 Global Biologics for Severe Asthma Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Biologics for Severe Asthma Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Biologics for Severe Asthma Sales by Application (2021-2032)
  2. 7.1.1 Global Biologics for Severe Asthma Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Biologics for Severe Asthma Sales Market Share by Application (2021-2032)
  4. 7.2 Global Biologics for Severe Asthma Revenue by Application (2021-2032)
  5. 7.2.1 Global Biologics for Severe Asthma Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Biologics for Severe Asthma Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Biologics for Severe Asthma Value Chain Analysis
  2. 8.1.1 Biologics for Severe Asthma Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Biologics for Severe Asthma Production Mode & Process
  5. 8.2 Biologics for Severe Asthma Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Biologics for Severe Asthma Distributors
  8. 8.2.3 Biologics for Severe Asthma Customers
9 Global Biologics for Severe Asthma Analyzing Market Dynamics
  1. 9.1 Biologics for Severe Asthma Industry Trends
  2. 9.2 Biologics for Severe Asthma Industry Drivers
  3. 9.3 Biologics for Severe Asthma Industry Opportunities and Challenges
  4. 9.4 Biologics for Severe Asthma Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst